Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 242

Sort by

Sort Order Select

Journal Articles

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

Ruochen Jia, Thomas Balligand, Vasyl Atamanyuk, Harini Nivarthi, Erica Xu, Leon Kutzner, Jakob Weinzierl, Audrey Nedelec, Stefan Kubicek, Roman Lesyk, Oleh Zagrijtschuk, Stefan N. Constantinescu, Robert Kralovics

Blood (2021) 137 (14): 1920–1931.

https://doi.org/10.1182/blood.2020006264

Published: 2021

Includes: Supplemental data

Journal Articles

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Gabriel Levy, Serge Carillo, Benjamin Papoular, Bruno Cassinat, Jean-Marc Zini, Emilie Leroy, Leila N. Varghese, Ilyas Chachoua, Jean-Philippe Defour, Steven O. Smith, Stefan N. Constantinescu

Blood (2020) 135 (12): 948–953.

https://doi.org/10.1182/blood.2019003240

Published: 2020

Includes: Supplemental data

Journal Articles

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Jessica L. Bridgford, Su Min Lee, Christine M. M. Lee, Paola Guglielmelli, Elisa Rumi, Daniela Pietra, Stephen Wilcox, Yash Chhabra, Alan F. Rubin, Mario Cazzola, Alessandro M. Vannucchi, Andrew J. Brooks, Matthew E. Call, Melissa J. Call

Blood (2020) 135 (4): 287–292.

https://doi.org/10.1182/blood.2019002561

Published: 2020

Includes: Supplemental data

Journal Articles

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Stephan Wilmes, PhD, Maximillian Hafer, BSc, Tess A Stanly, Ignacio Moraga, PhD, Joni Vuorio, PhD, Chetan Poojari, PhD, Vivek Sharma, PhD, Sara Löchte, PhD, Katiuska Pulgar Prieto, BSc, Julie A Tucker, PhD, Stevan R Hubbard, PhD, K.Christopher Garcia, PhD, Ilpo Vattulainen, PhD, Ian Hitchcock, PhD, Jacob Piehler, PhD

Blood (2019) 134 (Supplement_1): 2962.

https://doi.org/10.1182/blood-2019-129234

Published: 2019

Journal Articles

CD244 Marks Non-Functional Hematopoietic Stem Cells with a Mast Cell Signature after Induction of Endoplasmic Reticulum Stress

Valgardur Sigurdsson, PhD, Shuhei Koide, PhD, Visnja Radulovic, PhD, Els Mansell, PhD, Mark Van Der Garde, MSc, PhD, Tiit Örd, PhD, Tonis Örd, PhD, Kenichi Miharada, PhD

Blood (2019) 134 (Supplement_1): 2474.

https://doi.org/10.1182/blood-2019-128239

Published: 2019

Journal Articles

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Nathan Eaton, BS, Melissa M. Lee-Sundlov, PhD, Theresa A. Dlugi, PhD, Jon Wieser, BS, Haley E. Ramsey, PhDMSc, Martha Sola-Visner, MD, Karin M. Hoffmeister, MD, Hervé Falet, PhD

Blood (2019) 134 (Supplement_1): 2477.

https://doi.org/10.1182/blood-2019-126820

Published: 2019

Journal Articles

Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm

Brianna Craver, MS, Quy Nguyen, Gajalakshmi Ramanathan, PhD, Angela G. Fleischman, MD PhD

Blood (2019) 134 (Supplement_1): 2518.

https://doi.org/10.1182/blood-2019-123480

Published: 2019

Journal Articles

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Manjola Balliu, PhD, Laura Calabresi, PhD, Niccolò Bartalucci, PhDBSc, Laura Maggi, PhD, Francesco Annunziato, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 471.

https://doi.org/10.1182/blood-2019-123685

Published: 2019

Journal Articles

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Alison R. Moliterno, MD, Donna Marie Williams, PhD, Liping Li, MD PhD, Lingling Xian, MD PhD, Li Luo, PhD, Amy S. Duffield, MD PhD, Ophelia Rogers, Jerry L. Spivak, MD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 472.

https://doi.org/10.1182/blood-2019-131432

Published: 2019

Journal Articles

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Yihong Guan, PhD, Bhumika J. Patel, MD, Metis Hasipek, PhD, Dale Grabowski, BS, Hassan Awada, MD, Cassandra M Kerr, MS, Valeria Visconte, PhD, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 453.

https://doi.org/10.1182/blood-2019-131525

Published: 2019

Journal Articles

Zinc-Dependent Homomultimerization of Mutant Calreticulin Is Required for MPN Pathogenesis

Jeanne F Rivera, BSc, April Joy Baral, MSc, Rachael Smyth, MSc, Fatima Nadat, PhD, Emma Burman, BSc, Ghadah Alameer, MSc, Sally A Boxall, PhD, Brian R Jackson, PhD, Ann Mullally, MD, Edwin Chen, PhD

Blood (2019) 134 (Supplement_1): 312.

https://doi.org/10.1182/blood-2019-124005

Published: 2019

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

Ujunwa Cynthia Okoye-Okafor, MS,PhD, Komal Kumar Javarappa, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Joseph J Saad, MSc, BSc, Lumie Benard, Victor Thiruthuvanathan, M.S, Sally Cole, Madhuri Tatiparthy, M.S., Stephen Ruiz, B.Sc, Stefanie DeFronzo, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Amit Verma, MBBS, Aditi Shastri, MD, Caroline A Heckman, PhD, Britta Will, PhD

Blood (2019) 134 (Supplement_1): 1280.

https://doi.org/10.1182/blood-2019-131461

Published: 2019

Journal Articles

Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)

Anwar A. Sayed, MBBS, MSc, PhD, Amna Malik, PhD, Grace Ayoola, BSc., Elisa Lucchini, MD, Sasfia Candrianita, MD, Michelle H Tan, BSc, Camelia Vladescu, MSc, Deena Paul, Alice C J Hart, MBBS, BSc, MRCP, FRCPath(Haem), Ahmad Khoder, MD PhD MRCP, ASCP, Nesrina Imami, PhD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 2364.

https://doi.org/10.1182/blood-2019-122848

Published: 2019

Journal Articles

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

Golam Mohi, PhD, Avik Dutta, PhD, Dipmoy Nath, PhD, Yue Yang, PhD

Blood (2019) 134 (Supplement_1): 4200.

https://doi.org/10.1182/blood-2019-132038

Published: 2019

Journal Articles

Novel Insights Regarding Pediatric Essential Thrombocythemia

Assaf Arie Barg, Gili Kenet, Tami Livnat, PhD, Gal Goldstein, MD, Joanne Yacobovich, MD, Oded Gilad, MD, Orna Steinberg Shemer, MD MSc, Shoshana Revel-Vilk, MD, Hagit Miskin, MD, Amos Toren, MD PhD, Vered Shkalim, MD

Blood (2019) 134 (Supplement_1): 4191.

https://doi.org/10.1182/blood-2019-123865

Published: 2019

Journal Articles

Mutated CALR : tails from the crypt

Jerry L. Spivak

Blood (2019) 133 (25): 2630–2631.

https://doi.org/10.1182/blood-2019-04-901132

Published: 2019

Journal Articles

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Blood (2019) 133 (25): 2669–2681.

https://doi.org/10.1182/blood-2018-09-874578

Published: 2019

Includes: Supplemental data

Journal Articles

Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents

Komal Kumar Javarappa, PhD, Dimitrios Tsallos, BSc(Hons), MSc, Bulat Zagidullin, MSc, Joseph J Saad, MSc, BSc, Jing Tang, PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2018-99-118449

Published: 2018

Journal Articles

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

Dipmoy Nath, PhD, Avik Dutta, MSc, Yue Yang, BS, Clifford Whatcott, PhD, Steven L. Warner, PhD, Golam Mohi, PhD

Blood (2018) 132 (Supplement 1): 54.

https://doi.org/10.1182/blood-2018-99-119421

Published: 2018

NARROW

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

CD244 Marks Non-Functional Hematopoietic Stem Cells with a Mast Cell Signature after Induction of Endoplasmic Reticulum Stress

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Zinc-Dependent Homomultimerization of Mutant Calreticulin Is Required for MPN Pathogenesis

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

Novel Insights Regarding Pediatric Essential Thrombocythemia

Mutated CALR : tails from the crypt

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only